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Invasive Coronary
Vasoreactivity Testing to
Diagnose Microvascular
Dysfunction in Women*
Alison L. Bailey, MD, Susan S. Smyth, MD, PHD
Lexington, Kentucky
Fundamental gaps still exist in our understanding of car-
diovascular disease in women. Women are more likely to
suffer from coronary heart disease due to a higher prevalence
of very old age relative to men. Women tend to be protected
from the development and complications of coronary artery
disease (CAD) at younger ages, perhaps due to the benefi-
cial effects of estrogen on the vasculature. A number of
sex-related physiological differences might affect coronary
vascular function, including sex-based variations in vessel
anatomy, biomechanical properties (1), and endothelial
function. The vascular endothelium, in particular, plays a
key protective role in terms of preventing thrombosis,
smooth muscle cell proliferation, and vasoconstriction.
See page 646
In 1996, the National Institutes of Health launched the
WISE (Women’s Ischemia Syndrome Evaluation) study to
provide scientific evidence about presentation, diagnosis,
and progression of heart disease in women. Designed as a
multicenter cohort study, WISE followed more than 900
women for an average of nearly 4 years after clinically
indicated coronary angiography (2). Women presenting
with chest pain suggestive of angina and/or with abnormal
stress tests more often have nonobstructive CAD than their
male counterparts. A key finding from the WISE study was
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rom Boehringer-Ingelheim and The Medicines Company.the high burden of coronary microvascular dysfunction in
women presenting with ischemic symptoms but angio-
graphically normal vessels (3); up to one-half of symptom-
atic women had coronary microvascular dysfunction in the
absence of significant CAD. The impact of impaired
coronary vasoreactivity in women without obstructive
CAD can be significant: many experience persistent
symptoms or cardiovascular events that necessitate ex-
penditure of healthcare resources and affect their quality
of life (4,5). Previous results from the WISE study
demonstrated that impaired endothelial-mediated vaso-
dilatation in the absence of overt CAD predicts long-term
adverse cardiovascular events in women (4).
Microvascular dysfunction might involve both smooth
muscle cells or the endothelium (or both) and can be
measured in vivo by monitoring the vasodilator response to
pharmacological or mechanical (flow) challenge in either
peripheral or coronary vessels. Coronary reactivity can be
measured with invasive testing of endothelial function with
intracoronary infusion of acetylcholine, which promotes the
release of nitric oxide and endothelium-dependent vasodi-
lation followed by intracoronary administration of sodium
nitroprusside or adenosine, to assess endothelial-
independent function. Previously, the WISE investigators
validated an approach of assessing the functional integrity of
the coronary microvasculature in symptomatic women by
measuring coronary flow velocity response to adenosine and
monitoring coronary flow velocity reserve (CFR), defined as
the ratio of hyperemic time-averaged peak flow after adenosine
to time-averaged peak flow at baseline (6).
In this issue of JACC: Cardiovascular Interventions, Wei et
al. (7) report on the safety of invasive coronary reactivity
testing in women to diagnose microvascular disease. Among
293 symptomatic women without obstructive CAD who
underwent testing, 4 total adverse events occurred—2 of
which were deemed serious: a coronary dissection, and an
episode of coronary spasm leading to acute myocardial
infarction. Over the course of 5-year follow-up, the
overall rate of major adverse cardiac events in the population
was 8.2%. The investigators rightly conclude that the
immediate risk of testing is relatively low in comparison
with the overall event rate in this population.
The results of the procedure should change patient
management to justify performing an invasive test that
carries albeit a small (1%), but real risk of serious harm.
The strongest evidence in support of testing comes from the
documented benefit of angiotensin-converting enzyme in-
hibition in this population. In a subset of women in the
WISE study with microvascular dysfunction, randomization
to therapy with quinapril for 16 weeks improved both CFR
and symptoms, as compared with placebo therapy (8). The
benefit was observed in women with the most severe
microvascular dysfunction, as evidenced by the lowest CFR.
Given the strong link between inflammation and endothe-
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655lial dysfunction, women with microvascular dysfunction
might additionally benefit from high-dose statin therapy. In
patients with normal coronary arteries, high C-reactive
protein levels occur in association with abnormal coronary
vasoreactivity (9). In an isolated perfusion system,
C-reactive protein attenuates endothelial-dependent vaso-
dilatation of porcine coronary arterioles (10). Statins as a
class might exert beneficial pleiotropic effects on inflamma-
tion and endothelial function, thus rendering them useful in
the setting of microvascular dysfunction, although this
benefit remains theoretical at present. And certainly, regard-
less of symptoms, women should be counseled to adopt
healthy lifestyle habits that have been shown to delay the
development of obstructive CAD as well as improve mark-
ers of endothelial dysfunction. These would include total
abstinence from tobacco, moderate physical activity, and
achievement of an ideal weight.
Are there other less invasive procedures that could sub-
stitute for invasive coronary reactivity testing to establish the
diagnosis of coronary microvascular dysfunction? Lipid and
hormone levels, blood pressure, and left ventricular function
do not seem to predict coronary velocity response to
intracoronary adenosine, although age and years after
menopause might (3). Overall, traditional atherosclerotic
risk factors account for 20% of the observed variability in
CFR in this patient population (11). Several methods for
noninvasive peripheral measurements exist on the basis of
Doppler or finger arterial-pulsatile volume changes. Digital
reactive hyperemia peripheral arterial tonometry correlates
with nonobstructive CAD in women with symptoms of
angina referred for coronary angiography (12), and is
inexpensive, portable, and easy to use. However, the tech-
nique provides only a surrogate marker for coronary func-
tion without all the information that can be obtained from
direct, invasive measurements. Eventually, imaging modal-
ities such as cardiac magnetic resonance imaging with
pharmacological stress and gadolinium as a flow tracer,
might replace invasive testing but at present invasive coro-
nary reactivity remains the gold standard. By providing an
estimate of the risk in women with angina, the WISE study
continues its remarkable impact on advancing understand-
ing of the heart health of women and sex-based differences
in ischemic vascular disease.
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